{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-25-000053","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.559880+00:00","generated_at":"2026-05-23T04:30:35.626200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised","bullets":["Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.","Jakafi net product rev $709M (+24%); full-year 2025 guidance raised to $2,950-$3,000M.","Opzelura net rev $119M (+38%); Niktimvo launch rev $14M in first two months.","Povorcitinib meets primary endpoints in Phase 3 HS and Phase 2 CSU; supports regulatory submission.","Cash and marketable securities $2.4B; pipeline progress across MPN, oncology, and IAI programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-25-000053","json":"https://secwatch.observer/filing/0000879169-25-000053.json","markdown":"https://secwatch.observer/filing/0000879169-25-000053.md","text":"https://secwatch.observer/filing/0000879169-25-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/0000879169-25-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/incy-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:30:35.626200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}